Correction to: Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Heart Failure Events in Patients with Type 2 Diabetes Mellitus: A Cost Per Outcome Analysis (Clinical Drug Investigation, (2020), 40, 7, (665-669), 10.1007/s40261-020-00929-z)

Ronen Arbel; Enis Aboalhasan; Ariel Hammerman; Joseph Azuri

doi:10.1007/s40261-020-00932-4

Correction to: Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Heart Failure Events in Patients with Type 2 Diabetes Mellitus: A Cost Per Outcome Analysis (Clinical Drug Investigation, (2020), 40, 7, (665-669), 10.1007/s40261-020-00929-z)

Ronen Arbel^*, Enis Aboalhasan, Ariel Hammerman, Joseph Azuri

^*Corresponding author for this work

Clinical Departments

Research output: Contribution to journal › Comment/debate

Abstract

The original version of this article unfortunately contained a mistake. The correct information is given below.

Original language	English
Pages (from-to)	773
Number of pages	1
Journal	Clinical Drug Investigation
Volume	40
Issue number	8
DOIs	https://doi.org/10.1007/s40261-020-00932-4
State	Published - 1 Aug 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s40261-020-00932-4

Fingerprint

Dive into the research topics of 'Correction to: Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Heart Failure Events in Patients with Type 2 Diabetes Mellitus: A Cost Per Outcome Analysis (Clinical Drug Investigation, (2020), 40, 7, (665-669), 10.1007/s40261-020-00929-z)'. Together they form a unique fingerprint.

Cite this

Arbel, R., Aboalhasan, E., Hammerman, A., & Azuri, J. (2020). Correction to: Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Heart Failure Events in Patients with Type 2 Diabetes Mellitus: A Cost Per Outcome Analysis (Clinical Drug Investigation, (2020), 40, 7, (665-669), 10.1007/s40261-020-00929-z). Clinical Drug Investigation, 40(8), 773. https://doi.org/10.1007/s40261-020-00932-4

Arbel, Ronen ; Aboalhasan, Enis ; Hammerman, Ariel et al. / Correction to : Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Heart Failure Events in Patients with Type 2 Diabetes Mellitus: A Cost Per Outcome Analysis (Clinical Drug Investigation, (2020), 40, 7, (665-669), 10.1007/s40261-020-00929-z). In: Clinical Drug Investigation. 2020 ; Vol. 40, No. 8. pp. 773.

@article{74c5326ea9024419907988d0cad228e6,

title = "Correction to: Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Heart Failure Events in Patients with Type 2 Diabetes Mellitus: A Cost Per Outcome Analysis (Clinical Drug Investigation, (2020), 40, 7, (665-669), 10.1007/s40261-020-00929-z)",

abstract = "The original version of this article unfortunately contained a mistake. The correct information is given below.",

author = "Ronen Arbel and Enis Aboalhasan and Ariel Hammerman and Joseph Azuri",

note = "Publisher Copyright: {\textcopyright} 2020, Springer Nature Switzerland AG.",

year = "2020",

month = aug,

day = "1",

doi = "10.1007/s40261-020-00932-4",

language = "אנגלית",

volume = "40",

pages = "773",

journal = "Clinical Drug Investigation",

issn = "1173-2563",

publisher = "Adis International Ltd",

number = "8",

}

Arbel, R, Aboalhasan, E, Hammerman, A & Azuri, J 2020, 'Correction to: Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Heart Failure Events in Patients with Type 2 Diabetes Mellitus: A Cost Per Outcome Analysis (Clinical Drug Investigation, (2020), 40, 7, (665-669), 10.1007/s40261-020-00929-z)', Clinical Drug Investigation, vol. 40, no. 8, pp. 773. https://doi.org/10.1007/s40261-020-00932-4

Correction to : Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Heart Failure Events in Patients with Type 2 Diabetes Mellitus: A Cost Per Outcome Analysis (Clinical Drug Investigation, (2020), 40, 7, (665-669), 10.1007/s40261-020-00929-z). / Arbel, Ronen; Aboalhasan, Enis; Hammerman, Ariel et al.

In: Clinical Drug Investigation, Vol. 40, No. 8, 01.08.2020, p. 773.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Correction to

T2 - Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Heart Failure Events in Patients with Type 2 Diabetes Mellitus: A Cost Per Outcome Analysis (Clinical Drug Investigation, (2020), 40, 7, (665-669), 10.1007/s40261-020-00929-z)

AU - Arbel, Ronen

AU - Aboalhasan, Enis

AU - Hammerman, Ariel

AU - Azuri, Joseph

PY - 2020/8/1

Y1 - 2020/8/1

N2 - The original version of this article unfortunately contained a mistake. The correct information is given below.

AB - The original version of this article unfortunately contained a mistake. The correct information is given below.

UR - http://www.scopus.com/inward/record.url?scp=85086014136&partnerID=8YFLogxK

U2 - 10.1007/s40261-020-00932-4

DO - 10.1007/s40261-020-00932-4

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.comment???

C2 - 32506236

AN - SCOPUS:85086014136

SN - 1173-2563

VL - 40

SP - 773

JO - Clinical Drug Investigation

JF - Clinical Drug Investigation

IS - 8

ER -

Arbel R, Aboalhasan E, Hammerman A, Azuri J. Correction to: Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Heart Failure Events in Patients with Type 2 Diabetes Mellitus: A Cost Per Outcome Analysis (Clinical Drug Investigation, (2020), 40, 7, (665-669), 10.1007/s40261-020-00929-z). Clinical Drug Investigation. 2020 Aug 1;40(8):773. doi: 10.1007/s40261-020-00932-4

Correction to: Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Heart Failure Events in Patients with Type 2 Diabetes Mellitus: A Cost Per Outcome Analysis (Clinical Drug Investigation, (2020), 40, 7, (665-669), 10.1007/s40261-020-00929-z)

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this